Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Alzheimer's Disease

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 126 articles:
HTML format
Text format



Single Articles


    May 2018
  1. LI D, Donohue MC
    Disease progression models for dominantly-inherited Alzheimer's disease.
    Brain. 2018;141:1244-1246.
    PubMed     Text format    


  2. HANSSON O, Mormino EC
    Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?
    Brain. 2018;141:1241-1244.
    PubMed     Text format    


    April 2018
  3. VOGEL JW, Vachon-Presseau E, Pichet Binette A, Tam A, et al
    Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.
    Brain. 2018 Apr 23. pii: 4969934. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. SABRI O, Meyer PM, Graf S, Hesse S, et al
    Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Brain. 2018 Apr 17. pii: 4974320. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. MISHRA S, Blazey TM, Holtzman DM, Cruchaga C, et al
    Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE varepsilon4 genotype.
    Brain. 2018 Apr 17. pii: 4974818. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. MCALEESE KE, Walker L, Colloby SJ, Taylor JP, et al
    Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969931. doi: 10.1093.
    PubMed     Text format    


  7. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?
    Brain. 2018 Apr 13. pii: 4969932. doi: 10.1093.
    PubMed     Text format    


    March 2018
  8. HAMELIN L, Lagarde J, Dorothee G, Potier MC, et al
    Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
    Brain. 2018 Mar 28. pii: 4955843. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. OXTOBY NP, Young AL, Cash DM, Benzinger TLS, et al
    Data-driven models of dominantly-inherited Alzheimer's disease progression.
    Brain. 2018 Mar 22. pii: 4951528. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. JACK CR JR, Wiste HJ, Schwarz CG, Lowe VJ, et al
    Longitudinal tau PET in ageing and Alzheimer's disease.
    Brain. 2018 Mar 12. pii: 4929907. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. CHHATWAL JP, Schultz AP, Johnson KA, Hedden T, et al
    Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.
    Brain. 2018 Mar 7. pii: 4924520. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. NAKAMURA A, Cuesta P, Fernandez A, Arahata Y, et al
    Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Brain. 2018 Mar 7. pii: 4924218. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  13. FRANZMEIER N, Duzel E, Jessen F, Buerger K, et al
    Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.
    Brain. 2018 Feb 15. pii: 4862492. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. WHITWELL JL
    Multimodal neuroimaging provides insights into the biology of Alzheimer's disease.
    Brain. 2018;141:326-329.
    PubMed     Text format    


    January 2018
  15. HOENIG MC, Bischof GN, Seemiller J, Hammes J, et al
    Networks of tau distribution in Alzheimer's disease.
    Brain. 2018 Jan 5. pii: 4791255. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. RICHTER N, Beckers N, Onur OA, Dietlein M, et al
    Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Brain. 2018 Jan 4. pii: 4788772. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. MITO R, Raffelt D, Dhollander T, Vaughan DN, et al
    Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Brain. 2018 Jan 4. pii: 4788771. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  18. COPE TE, Rittman T, Borchert RJ, Jones PS, et al
    Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Dec 26. pii: 4775021. doi: 10.1093.
    PubMed     Text format    


  19. MAEZAWA I, Nguyen HM, Di Lucente J, Jenkins DP, et al
    Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
    Brain. 2017 Dec 18. pii: 4759461. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. LOWE VJ, Wiste HJ, Senjem ML, Weigand SD, et al
    Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Brain. 2017 Dec 8. pii: 4712020. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. FRANZMEIER N, Dyrba M
    Functional brain network architecture may route progression of Alzheimer's disease pathology.
    Brain. 2017;140:3077-3080.
    PubMed     Text format    


  22. MUTLU J, Landeau B, Gaubert M, de La Sayette V, et al
    Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Brain. 2017;140:3317-3328.
    PubMed     Text format    


  23. COLOM-CADENA M, Pegueroles J, Herrmann AG, Henstridge CM, et al
    Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies.
    Brain. 2017;140:3204-3214.
    PubMed     Text format     Abstract available


  24. SANTAMARIA-GARCIA H, Baez S, Reyes P, Santamaria-Garcia JA, et al
    A lesion model of envy and Schadenfreude: legal, deservingness and moral dimensions as revealed by neurodegeneration.
    Brain. 2017;140:3357-3377.
    PubMed     Text format     Abstract available


  25. PERRY DC, Brown JA, Possin KL, Datta S, et al
    Clinicopathological correlations in behavioural variant frontotemporal dementia.
    Brain. 2017;140:3329-3345.
    PubMed     Text format     Abstract available


  26. RODRIGUEZ-RODRIGUEZ P, Sandebring-Matton A, Merino-Serrais P, Parrado-Fernandez C, et al
    Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons.
    Brain. 2017;140:3269-3285.
    PubMed     Text format     Abstract available


    November 2017
  27. SHINOHARA M, Koga S, Konno T, Nix J, et al
    Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-beta42 in Alzheimer's disease.
    Brain. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. BUSTOS FJ, Ampuero E, Jury N, Aguilar R, et al
    Epigenetic editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.
    Brain. 2017 Nov 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. GRINBERG LT, Heinsen H
    Light at the beginning of the tunnel? Investigating early mechanistic changes in Alzheimer's disease.
    Brain. 2017;140:2770-2773.
    PubMed     Text format    


    October 2017
  30. DU F, Yu Q, Yan S, Hu G, et al
    PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease.
    Brain. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. BEJANIN A, Schonhaut DR, La Joie R, Kramer JH, et al
    Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Brain. 2017 Oct 7. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  32. RORABAUGH JM, Chalermpalanupap T, Botz-Zapp CA, Fu VM, et al
    Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.
    Brain. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. CHONG JSX, Liu S, Loke YM, Hilal S, et al
    Influence of cerebrovascular disease on brain networks in prodromal and clinical Alzheimer's disease.
    Brain. 2017 Sep 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. SCHOLL M, Ossenkoppele R, Strandberg O, Palmqvist S, et al
    Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease.
    Brain. 2017;140:2286-2294.
    PubMed     Text format     Abstract available


    August 2017
  35. DERRY PJ, Kent TA
    Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease.
    Brain. 2017;140:2069-2072.
    PubMed     Text format    


  36. KIM H, Yoo J, Shin J, Chang Y, et al
    Modelling APOE varepsilon3/4 allele-associated sporadic Alzheimer's disease in an induced neuron.
    Brain. 2017;140:2193-2209.
    PubMed     Text format     Abstract available


  37. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Text format     Abstract available


    July 2017
  38. JACOBS HIL, Hopkins DA, Mayrhofer HC, Bruner E, et al
    The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline.
    Brain. 2017 Jul 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Text format     Abstract available


  40. MARKUS HS
    Cerebrovascular abnormalities in Alzheimer's dementia: a more tractable treatment target?
    Brain. 2017;140:1822-1825.
    PubMed     Text format    


  41. KREISL WC
    Discerning the relationship between microglial activation and Alzheimer's disease.
    Brain. 2017;140:1825-1828.
    PubMed     Text format    


    June 2017
  42. GEORGE C, Gontier G, Lacube P, Francois JC, et al
    The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.
    Brain. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  43. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. DANSOKHO C, Aucouturier P, Dorothee G
    Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


  45. ALVES S, Churlaud G, Klatzmann D, Cartier N, et al
    Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


  46. TOSUN D, Landau S, Aisen PS, Petersen RC, et al
    Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals.
    Brain. 2017;140:1499-1512.
    PubMed     Text format     Abstract available


    April 2017
  47. HARDY J, De Strooper B
    Alzheimer's disease: where next for anti-amyloid therapies?
    Brain. 2017;140:853-855.
    PubMed     Text format    


  48. CARAVAGGIO F, Graff-Guerrero A
    Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity?
    Brain. 2017;140:865-867.
    PubMed     Text format    


    March 2017
  49. YU M, Engels MM, Hillebrand A, van Straaten EC, et al
    Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
    Brain. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. COULTHARD E, Knight M
    Refining Alzheimer's disease diagnosis with MRI.
    Brain. 2017;140:524-526.
    PubMed     Text format    


    February 2017
  52. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. HUSAIN M
    Alzheimer's disease: time to focus on the brain, not just molecules.
    Brain. 2017;140.
    PubMed     Text format    


    January 2017
  55. PASSAMONTI L, Vazquez Rodriguez P, Hong YT, Allinson KS, et al
    18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Jan 24. pii: aww340. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. HAYES JP, Logue MW, Sadeh N, Spielberg JM, et al
    Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
    Brain. 2017 Jan 11. pii: aww344. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. PONTECORVO MJ, Devous MD Sr, Navitsky M, Lu M, et al
    Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Brain. 2017 Jan 11. pii: aww334. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. CAPSONI S, Malerba F, Carucci NM, Rizzi C, et al
    The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


  60. AHMED RM, Landin-Romero R, Collet TH, van der Klaauw AA, et al
    Energy expenditure in frontotemporal dementia: a behavioural and imaging study.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


    December 2016
  61. ALVES S, Churlaud G, Audrain M, Michaelsen-Preusse K, et al
    Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.
    Brain. 2016 Dec 20. pii: aww330. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. DONG A, Toledo JB, Honnorat N, Doshi J, et al
    Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Brain. 2016 Dec 20. pii: aww319. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  63. ROGAEVA E, Schmitt-Ulms G
    Does BDNF Val66Met contribute to preclinical Alzheimer's disease?
    Brain. 2016;139.
    PubMed     Text format    


    September 2016
  64. JAMES BD, Wilson RS, Boyle PA, Trojanowski JQ, et al
    TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
    Brain. 2016.
    PubMed     Text format     Abstract available


  65. O'SULLIVAN MJ, Vann SD
    Amyloid imaging and Alzheimer's disease: the unsolved cases.
    Brain. 2016;139.
    PubMed     Text format    


  66. COHEN AD
    Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease.
    Brain. 2016;139.
    PubMed     Text format    


    August 2016
  67. TIWARI SS, Mizuno K, Ghosh A, Aziz W, et al
    Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss.
    Brain. 2016.
    PubMed     Text format     Abstract available


  68. LIM YY, Hassenstab J, Cruchaga C, Goate A, et al
    BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  69. HANSSON O, Gouras G
    Brain activity and Alzheimer's disease: a complex relationship.
    Brain. 2016;139.
    PubMed     Text format    


    July 2016
  70. LEWCZUK P, Kornhuber J
    Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


  71. PALMQVIST S, Mattsson N, Hansson O
    Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


    June 2016
  72. CHETELAT G, Ossenkoppele R, Villemagne VL, Perrotin A, et al
    Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  73. GORDON BA, Friedrichsen K, Brier M, Blazey T, et al
    The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


    May 2016
  74. WOODLING NS, Colas D, Wang Q, Minhas P, et al
    Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.
    Brain. 2016.
    PubMed     Text format     Abstract available


  75. OH H, Madison C, Baker S, Rabinovici G, et al
    Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  76. SARAZIN M, Lagarde J, Bottlaender M
    Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease.
    Brain. 2016;139.
    PubMed     Text format    


  77. THAL DR, Vandenberghe R
    Monitoring the progression of Alzheimer's disease with tau-PET.
    Brain. 2016;139.
    PubMed     Text format    


  78. SCHMAHMANN JD
    Cerebellum in Alzheimer's disease and frontotemporal dementia: not a silent bystander.
    Brain. 2016;139.
    PubMed     Text format    


    April 2016
  79. AGGLETON JP, Pralus A, Nelson AJ, Hornberger M, et al
    Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit.
    Brain. 2016.
    PubMed     Text format     Abstract available


  80. RABINOVICI GD
    Amyloid biomarkers: pushing the limits of early detection.
    Brain. 2016;139.
    PubMed     Text format    


  81. HARPER L, Fumagalli GG, Barkhof F, Scheltens P, et al
    MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


  82. HABES M, Erus G, Toledo JB, Zhang T, et al
    White matter hyperintensities and imaging patterns of brain ageing in the general population.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    March 2016
  83. HAMELIN L, Lagarde J, Dorothee G, Leroy C, et al
    Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


  84. OSSENKOPPELE R, Schonhaut DR, Scholl M, Lockhart SN, et al
    Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  85. PALMQVIST S, Mattsson N, Hansson O
    Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography.
    Brain. 2016.
    PubMed     Text format     Abstract available


  86. SCHWARZ AJ, Yu P, Miller BB, Shcherbinin S, et al
    Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Brain. 2016.
    PubMed     Text format     Abstract available


  87. DURAN-ANIOTZ C, Cornejo VH, Hetz C
    Targeting endoplasmic reticulum acetylation to restore proteostasis in Alzheimer's disease.
    Brain. 2016;139.
    PubMed     Text format    


  88. SCHOTT JM, Fox NC
    Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?
    Brain. 2016;139.
    PubMed     Text format    


  89. DUZEL E, van Praag H, Sendtner M
    Can physical exercise in old age improve memory and hippocampal function?
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    February 2016
  90. SPANGENBERG EE, Lee RJ, Najafi AR, Rice RA, et al
    Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


  91. GUO CC, Tan R, Hodges JR, Hu X, et al
    Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia.
    Brain. 2016.
    PubMed     Text format     Abstract available


  92. DANSOKHO C, Ait Ahmed D, Aid S, Toly-Ndour C, et al
    Regulatory T cells delay disease progression in Alzheimer-like pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


    January 2016
  93. RODRIGUEZ-VIEITEZ E, Saint-Aubert L, Carter SF, Almkvist O, et al
    Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  94. ZHU QB, Unmehopa U, Bossers K, Hu YT, et al
    MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  95. PENG Y, Kim MJ, Hullinger R, O'Riordan KJ, et al
    Improved proteostasis in the secretory pathway rescues Alzheimer's disease in the mouse.
    Brain. 2016.
    PubMed     Text format     Abstract available


  96. OLMOS-ALONSO A, Schetters ST, Sri S, Askew K, et al
    Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


  97. JAGUST W
    Is amyloid-beta harmful to the brain? Insights from human imaging studies.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    December 2015
  98. HAAS LT, Salazar SV, Kostylev MA, Um JW, et al
    Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  99. KIMBROUGH IF, Robel S, Roberson ED, Sontheimer H, et al
    Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  100. SORG C, Grothe MJ
    The complex link between amyloid and neuronal dysfunction in Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format    


    November 2015
  101. JONES DT, Knopman DS, Gunter JL, Graff-Radford J, et al
    Cascading network failure across the Alzheimer's disease spectrum.
    Brain. 2015.
    PubMed     Text format     Abstract available


  102. RYAN NS, Rossor MN, Fox NC
    Alzheimer's disease in the 100 years since Alzheimer's death.
    Brain. 2015.
    PubMed     Text format    


  103. FLETCHER PD, Downey LE, Golden HL, Clark CN, et al
    Pain and temperature processing in dementia: a clinical and neuroanatomical analysis.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    October 2015
  104. FAN Z, Okello AA, Brooks DJ, Edison P, et al
    Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  105. ESCOTT-PRICE V, Sims R, Bannister C, Harold D, et al
    Common polygenic variation enhances risk prediction for Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  106. MAYA Y, Okumura Y, Kobayashi R, Onishi T, et al
    Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-beta.
    Brain. 2015.
    PubMed     Text format     Abstract available


  107. KULLMANN DM
    Editorial.
    Brain. 2015;138.
    PubMed     Text format    


  108. TAN RH, Kril JJ, Fatima M, McGeachie A, et al
    TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    September 2015
  109. PORTELIUS E, Zetterberg H, Skillback T, Tornqvist U, et al
    Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


    August 2015
  110. BRAAK H, Del Tredici K
    The preclinical phase of the pathological process underlying sporadic Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  111. FRINGS L, Hellwig S, Spehl TS, Bormann T, et al
    Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  112. RAMANAN VK, Risacher SL, Nho K, Kim S, et al
    GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.
    Brain. 2015.
    PubMed     Text format     Abstract available


  113. CLARK CN, Warren JD
    Music, memory and mechanisms in Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format    


    July 2015
  114. TOLEDO JB, Zetterberg H, van Harten AC, Glodzik L, et al
    Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Brain. 2015.
    PubMed     Text format     Abstract available


  115. DJELTI F, Braudeau J, Hudry E, Dhenain M, et al
    CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  116. OSSENKOPPELE R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, et al
    The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
    Brain. 2015.
    PubMed     Text format     Abstract available


  117. ANTONIADES CA, Kennard C
    Oculomotor abnormalities in posterior cortical atrophy: are they different from those in Alzheimer's disease after all?
    Brain. 2015;138.
    PubMed     Text format    


  118. CUMMINGS DM, Liu W, Portelius E, Bayram S, et al
    First effects of rising amyloid-beta in transgenic mouse brain: synaptic transmission and gene expression.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  119. SHAKESPEARE TJ, Kaski D, Yong KX, Paterson RW, et al
    Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    June 2015
  120. KORONYO Y, Salumbides BC, Sheyn J, Pelissier L, et al
    Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  121. JACOBSEN JH, Stelzer J, Fritz TH, Chetelat G, et al
    Why musical memory can be preserved in advanced Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  122. DICKSON DW, Murray ME
    Intraneuronal amyloid-beta accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration.
    Brain. 2015;138.
    PubMed     Text format    


    May 2015
  123. KROHN M, Bracke A, Avchalumov Y, Schumacher T, et al
    Accumulation of murine amyloid-beta mimics early Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  124. WANG DB, Kinoshita Y, Kinoshita C, Uo T, et al
    Loss of endophilin-B1 exacerbates Alzheimer's disease pathology.
    Brain. 2015.
    PubMed     Text format     Abstract available


  125. VILLENEUVE S, Rabinovici GD, Cohn-Sheehy BI, Madison C, et al
    Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
    Brain. 2015.
    PubMed     Text format     Abstract available


  126. SHULTZ SR, Wright DK, Zheng P, Stuchbery R, et al
    Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: